GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Dec 19, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, company-update, sec-filing
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
GSK plc announced on December 19, 2025, that it purchased a certain number of its own ordinary shares, each with a nominal value of 31 1/4 pence. The transactions were executed through its broker, BNP Paribas SA. This filing is a report of foreign private issuer activity.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any new or significant risks.
Key Players & Entities
- GSK plc (company) — Registrant
- BNP Paribas SA (company) — Broker executing share purchases
- 31 1/4 pence (dollar_amount) — Nominal value of ordinary shares purchased
- December 2025 (date) — Reporting period for the transaction
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically detailing transactions in GSK plc's own shares during the month of December 2025.
Who is acting as the broker for GSK plc's share repurchases?
BNP Paribas SA is acting as the broker for GSK plc's transactions in its own shares.
What is the nominal value of the ordinary shares GSK plc is purchasing?
The ordinary shares of GSK plc that are being purchased have a nominal value of 31 1/4 pence each.
Does GSK plc file annual reports under Form 20-F or Form 40-F?
GSK plc indicates that it files annual reports under cover of Form 20-F.
When was the company formerly known as GlaxoSmithKline plc?
The company was formerly known as GlaxoSmithKline plc, with a date of name change to GSK plc in 2001.
Filing Stats: 3,066 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-12-19 06:51:50
Filing Documents
- a1943m.htm (6-K) — 3096KB
- 0001654954-25-014129.txt ( ) — 3098KB
From the Filing
IN OWN SHARES a1943m UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of December 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 18 December 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 235,000 Lowest price paid per share (GBp): 1,797.50p Highest price paid per share (GBp): 1,820.00p Volume-weighted average price paid per share (GBp): 1,810.34p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 14,321,733 ordinary shares.   Following the above purchase, the Company will hold 239,786,577 ordinary shares in treasury and have 4,075,654,506 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,075,654,506. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.88 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:     18 December 2025 Investment firm:         BNP Paribas SA   Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   21,837   1,820.00p   1,799.00p   1,811.20p   CHIX   71,699   1,820.00p   1,797.50p   1,809.94p   XLON   141,464   1,820.00p   1,797.50p   1,810.41p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   164   1818.5   XLON   18-Dec-2025   08:00:29   20251218160184291   37   1818.5   CHIX   18-Dec-2025   08:00:29   20251218160184293   26   1818.5   BATE   18-Dec-2025   08:01:16   20251218160184729   164   1818.5   CHIX   18-Dec-2025   08:01:16   20251218160184731   164